Literatur
- 1 Diener H C, Hacke W. Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart:
Thieme 2003 (s. a. www.dgn.org)
- 2
Hacke W, Kaste M, Bogousslavsky J, Brainin M, Chamorro A, Lees K, Leys D, Kwiecinski H,
Toni P, Langhorne P, Diener C, Hennerici M, Ferro J, Sivenius J, Gunnar N, Bath P,
Olsen T S, Gugging M.
European Stroke Initiative Executive Committee and the EUSI Writing Committee. European
Stroke Initiative Recommendations for Stroke Management-update 2003.
Cerebrovasc Dis.
2003;
16
311-337
- 3
Vutuc C, Haidinger G, Waldhoer T.
Descriptive epidemiology of cerebrovascular disorders in Austria.
Med Wochenschr.
1997;
147
30-33
- 4
Gelder I C van, Hagens V E, Bosker H A, Kingma J H, Kamp O, Kingma T, Said S A, Darmanata J I,
Timmermans A J, Tijssen J G, Crijns H J.
Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study
Group. A comparison of rate control and rhythm control in patients with recurrent
persistent atrial fibrillation.
N Engl J Med.
2002;
347
1834-1840
- 5
Hart R G.
Stroke prevention in atrial fibrillation.
Curr Cardiol Rep.
2000;
2
51-55
- 6
Hart R G, Halperin J L.
Atrial fibrillation and stroke: concepts and controversies.
Stroke.
2001;
32
803-808
- 7
Olsson S B.
Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention
with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients
with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial.
Lancet.
2003;
362
1691-1698
- 8
Salem D N, Levine H J, Pauker S G, Eckman M H, Daudelin D H.
Antithrombotic therapy in valvular heart disease.
Chest.
1998;
114
590S-601S
- 9
Hardman S M, Cowie M R.
Anticoagulation in heart disease.
BMJ.
1999;
318
238-244
- 10
Gilon D, Buonanno F S, Joffe M M, Leavitt M, Marshall J E, Kistler J P, Levine R A.
Lack of evidence of an association between mitral-valve prolapse and stroke in young
patients.
N Engl J Med.
1999;
341
8-13
- 11
ECST .
Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final
results of the MRC European Carotid Surgery Trial (ECST).
Lancet.
1998;
351
379-387
- 12
Hobson 2nd R W, Weiss D G, Fields W S, Goldstone J, Moore W S, Towne J B, Wright C B.
Efficacy of carotid endarterectomy for asymptomatic carotid stenosis. The Veterans
Affairs Cooperative Study Group.
N Engl J Med.
1993;
328
221-227
- 13
The CASANOVA Study Group .
Carotid surgery versus medical therapy in asymptomatic carotid stenosis.
Stroke.
1991;
22
1229-1235
- 14
Executive Committee for the Asymptomatic Carotid Atherosclerosis Study .
Endarterectomy for asymptomatic carotid artery stenosis.
JAMA.
1995;
273
1421-1428
- 15
Baker W H, Howard V J, Howard G, Toole J F. for the ACAS investigators .
Effect of contralateral occlusion on long-term efficacy of endarterectomy in the Asymptomatic
Carotid Atherosclerosis Study (ACAS).
Stroke.
2000;
31
2330-2334
- 16 Wolf P A. Hypertension. In: Hachinski V (eds.). Stroke prevention. Oxford, New
York: Oxford University Press 2001: 93-106
- 17
Collins R, Peto R, MacMahon S, Hebert P, Fiebach N H, Eberlein K A, Godwin J, Qizilbash N,
Taylor J O, Hennekens C H.
Blood pressure, stroke and coronary heart disease. Part 2, short-term reductions in
blood pressure: overview of randomized drug trials in their epidemiological context.
Lancet.
1990;
335
827-838
- 18
Hansson L, Lindholm L H, Ekbom T, Dahlöf B, Lanke J, Scherstén B, Wester P O, Hedner T.
Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular
mortality and morbidity the Swedish Trial in old patients with hypertension-2 study.
Lancet.
1999;
354
1751-1756
- 19
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group .
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting
enzyme inhibitor or calcium channel blocker vs diuretic. The antihypertensive and
lipid-lowering treatment to prevent heart attack trial (ALLHAT).
JAMA.
2002;
288
2981-2997
- 20
Lindholm L H, Ibsen H, Dahlof B, Devereux R B, Beevers G, de Faire U, Fyhrquist F,
Julius S, Kjeldsen S E, Kristiansson K, Lederballe-Pedersen O, Nieminen M S, Omvik P,
Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S. , The LIFE Study Group .
Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention
for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Lancet.
2002;
359
1004-1010
- 21
Heart Outcomes Prevention Evaluation (HOPE) Study Investigators .
Effects of ramipril on cardiovascular and microvasular outcomes in people with diabetes
mellitus: results of the HOPE study and MICRO-HOPE substudy.
Lancet.
2000;
355
253-259
- 22
Goldstein L B, Adams R, Becker K J, Furberg C D, Gorelick P B, Hademenos G, Hill M,
Howard G, Howard V J, Jacobs B, Levine S R, Mosca L, Sacco R L, Sherman D G, Wolf P A,
del Zoppo G J.
Primary prevention of ischemic stroke: A statement for healthcare professionals from
the Stroke Council of the American Heart Association.
Stroke.
2001;
32
280-299
- 23
White H D, Simes R J, Anderson N E, Hankey G J, Watson J DG, Hunt D, Colquhoun D M,
Glasziou P, MacMahon S, Kirby A C, West M J, Tonkin A M.
Pravastatin therapy and the risk of stroke.
N Engl J Med.
2000;
343
317-326
- 24
Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S,
Herd A, Khan S, Newby L K, Waters D, Vittinghoff E, Wenger N. and the HERS Research
Group .
Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin
Replacement Study follow-up (HERS II).
JAMA.
2002;
288
99-101
- 25
Hillborn M, Numminnen H, Juvela S.
Recent heavy drinking of alcohol and embolic stroke.
Stroke.
1999;
30
2307-2312
- 26
Steering Committee of the Physicians Health Study Research Group .
Final report on the aspirin component of the ongoing physicians health study.
N Engl J Med.
1989;
321
129-135
- 27
Iso H, Hennekens C H, Stampfer M J, Rexrode K M, Colditz G A, Speizer F E, Willett W C,
Mannson J E.
Prospective study of aspirin use and risk of stroke in women.
Stroke.
1999;
30
1764-1771
- 28
Hart R G, Halperin J L, McBride R, Benavente O, Man-Son-Hing M, Kronmal R A.
Aspirin for the primary prevention of stroke and other major vascular events. Meta-analysis
and hypotheses.
Arch Neurol.
2000;
57
326-332
- 29
Collaborative Group of the Primary Prevention Project (PPP) .
Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial
in general practice.
Lancet.
2001;
357
89-95
PD Dr. med. Elmar Busch
Klinik für Neurologie, Universitätsklinikum Essen
Hufelandstr. 55
45122 Essen
Email: elmar.busch@uni-essen.de
